Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis
Akira Okita(Tohoku University), Chikashi Ishioka(Tohoku University), Sho Umegaki(Tohoku University), Hisatsugu Ohori(Tohoku University Hospital), Keigo Komine(Tohoku University), Ken Saijo(Tohoku University), Masanobu Takahashi(Shibaura Institute of Technology), Yoshifumi Kawamura(Tohoku University), Makio Gamoh(Osaki Citizen Hospital), Hidekazu Shirota(Tohoku University), Kota Ouchi(Tohoku University), Hidekazu Takahashi(Boston Medical Center), Sakura Hiraide(Tohoku University Hospital), Hiroo Imai(Tohoku University), Yuko Sato(Tohoku University), Yoshinari Okada(Tohoku University), Shin Takahashi(Institute of Aging), Masahiro Takahashi(Tohoku University Hospital)
Cited by 7
Related Papers
Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1
|Nature|2011|388
MiR‐133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures
|The EMBO Journal|2014|302
Human protein factory for converting the transcriptome into an in vitro–expressed proteome
|Nature Methods|2008|269
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244